IFx-Hu20 is under clinical development by Morphogenesis and currently in Phase I for Basal Cell Carcinoma (Basal Cell Epithelioma). According to GlobalData, Phase I drugs for Basal Cell Carcinoma (Basal Cell Epithelioma) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IFx-Hu20’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IFx-Hu20 overview

IFx-Hu20 is under development for the treatment of cutaneous melanoma, Merkel cell carcinoma, head and neck cancer, basal cell carcinoma, gastric cancer, colorectal cancer, non-melanoma skin cancers and cutaneous squamous cell carcinoma. The therapeutic candidate is administered through intralesional route. It comprises of plasmid DNA coding for Emm55 Streptococcal antigen. It is developed based on ImmuneFx technology. The therapeutic candidate is composed of the drug substance pAc/emm55 (pDNA) complexed with the two excipients in vivo-jetPEI (linear polyethylenimine), a transfection reagent, and dextrose, a pDNA/polyethylenimine complex stabilizer.

Morphogenesis overview

Morphogenesis is a developer of novel cell and gene therapies to detect, monitor and control cancer. The company manufactures products based on distinct and synergistic technology platforms. It uses technologies such as immunefx cancer immuno therapies, the polymer antibody cell separation device, Morphogenesis allograft tissue with compatible HLA and bluebio. Morphogenesis also develops stem cell banks, which can be used to generate cells, tissues and organs. The company offers products for the treatment of infectious diseases, cancer and other chronic diseases. Morphogenesis is headquartered in Tampa, Florida, the US.

For a complete picture of IFx-Hu20’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.